BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 20562789)

  • 1. Metabolic syndrome - the consequence of lifelong treatment of bipolar affective disorder.
    Dadić-Hero E; Ruzić K; Grahovac T; Petranović D; Graovac M; Palijan TZ
    Psychiatr Danub; 2010 Jun; 22(2):381-4. PubMed ID: 20562789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of bipolar disorders and metabolic syndrome: implications for primary care.
    Bell PF; McKenna JP; Roscoe BM
    Postgrad Med; 2009 Sep; 121(5):140-4. PubMed ID: 19820282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls.
    Elmslie JL; Porter RJ; Joyce PR; Hunt PJ; Shand BI; Scott RS
    Aust N Z J Psychiatry; 2009 Jan; 43(1):53-60. PubMed ID: 19085528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical risk in patients with bipolar disorder and schizophrenia.
    Newcomer JW
    J Clin Psychiatry; 2006; 67 Suppl 9():25-30; discussion 36-42. PubMed ID: 16965186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bipolar disorder and metabolic syndrome: comorbidity or side effects of treatment of bipolar disorder.
    Babić D; Maslov B; Martinac M; Nikolić K; Uzun S; Kozumplik O
    Psychiatr Danub; 2010 Mar; 22(1):75-8. PubMed ID: 20305595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational polypharmacy in the bipolar affective disorders.
    Post RM; Ketter TA; Pazzaglia PJ; Denicoff K; George MS; Callahan A; Leverich G; Frye M
    Epilepsy Res Suppl; 1996; 11():153-80. PubMed ID: 9294735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obesity and metabolic syndrome in a psychiatric rehabilitation service.
    Tirupati S; Chua LE
    Aust N Z J Psychiatry; 2007 Jul; 41(7):606-10. PubMed ID: 17558623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosing and treating comorbid (complicated) bipolar disorder.
    McElroy SL
    J Clin Psychiatry; 2004; 65 Suppl 15():35-44. PubMed ID: 15554795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents.
    Schneiderhan ME; Batscha CL; Rosen C
    Pharmacotherapy; 2009 Aug; 29(8):975-87. PubMed ID: 19637951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modal subcomponents of metabolic syndrome in patients with bipolar disorder.
    Cardenas J; Frye MA; Marusak SL; Levander EM; Chirichigno JW; Lewis S; Nakelsky S; Hwang S; Mintz J; Altshuler LL
    J Affect Disord; 2008 Feb; 106(1-2):91-7. PubMed ID: 17628693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database.
    Sicras A; Rejas J; Navarro R; Serrat J; Blanca M
    Bipolar Disord; 2008 Jul; 10(5):607-16. PubMed ID: 18657245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders.
    McIntyre RS; Alsuwaidan M; Goldstein BI; Taylor VH; Schaffer A; Beaulieu S; Kemp DE;
    Ann Clin Psychiatry; 2012 Feb; 24(1):69-81. PubMed ID: 22303523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight gain--as possible predictor of metabolic syndrome.
    Grahovac T; Ružić K; Dadić-Hero E; Sepić-Grahovac D; Sabljić V
    Psychiatr Danub; 2011 Mar; 23(1):105-7. PubMed ID: 21448110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical risk in patients with bipolar disorder and schizophrenia.
    Newcomer JW
    J Clin Psychiatry; 2006 Nov; 67(11):e16. PubMed ID: 17201046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder.
    van Winkel R; De Hert M; Van Eyck D; Hanssens L; Wampers M; Scheen A; Peuskens J
    Bipolar Disord; 2008 Mar; 10(2):342-8. PubMed ID: 18271914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metabolic testing rates after initiation of antipsychotic treatment in persons initially treated by conventional mood-stabilizers].
    Verdoux H; Gaudron Y; Auleley GR; Deligne J; Blum-Boisgard C; Thiébaut A; Tournier M
    Encephale; 2013 May; 39 Suppl 1():S22-8. PubMed ID: 23246328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study.
    Guo JJ; Keck PE; Corey-Lisle PK; Li H; Jiang D; Jang R; L'Italien GJ
    Pharmacotherapy; 2007 Jan; 27(1):27-35. PubMed ID: 17192159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prevalence of metabolic disturbances in patients with bipolar disorder in Taiwan.
    Chang HH; Chou CH; Chen PS; Gean PW; Huang HC; Lin CY; Yang YK; Lu RB
    J Affect Disord; 2009 Sep; 117(1-2):124-9. PubMed ID: 19193445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients.
    Morrato EH; Cuffel B; Newcomer JW; Lombardo I; Kamat S; Barron J
    J Clin Psychopharmacol; 2009 Feb; 29(1):26-32. PubMed ID: 19142103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.